A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

2020/10/01 by Patrick A. Ott, Siwen Hu-Lieskovan, Siwen Hu‐Lieskovan +44 · 10 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses #vaccines and immunoinformatics approaches

paper · pdf · doi:10.1016/j.cell.2020.08.053

crossref issued 2020/10/01 · crossref published 2020/10/01 · crossref published-print 2020/10/01 · openalex publication_date 2020/10/01 · crossref created 2020/10/15 · crossref deposited 2025/09/25 · openalex created_date 2025/10/10 · crossref indexed 2026/07/24 · openalex updated_date 2026/07/29

Cited by

• The Future of Personalized Cancer Vaccines
• Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
• T cells in health and disease
• The Landmark Series: Cancer Vaccines for Solid Tumors
• Clinical development of cancer vaccines
• Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial
• XCL1-secreting CEA CAR-T cells enhance endogenous CD8+ T cell responses to tumor neoantigens to confer a long-term antitumor immunity
• Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications
• PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
• Cancer vaccines: the next immunotherapy frontier